Compare ELVN & SBCF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELVN | SBCF |
|---|---|---|
| Founded | 2016 | 1926 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.9B |
| IPO Year | 2020 | 2009 |
| Metric | ELVN | SBCF |
|---|---|---|
| Price | $41.67 | $30.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $43.40 | $38.00 |
| AVG Volume (30 Days) | 570.7K | ★ 810.8K |
| Earning Date | 05-11-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 2.43% |
| EPS Growth | 3.17 | ★ 10.56 |
| EPS | N/A | ★ 0.29 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $45.04 |
| Revenue Next Year | N/A | $6.30 |
| P/E Ratio | ★ N/A | $105.09 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.79 | $24.46 |
| 52 Week High | $48.53 | $35.55 |
| Indicator | ELVN | SBCF |
|---|---|---|
| Relative Strength Index (RSI) | 51.24 | 46.53 |
| Support Level | $16.84 | $29.26 |
| Resistance Level | $45.14 | $32.23 |
| Average True Range (ATR) | 2.38 | 0.72 |
| MACD | -0.21 | -0.02 |
| Stochastic Oscillator | 48.17 | 42.66 |
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Seacoast Banking Corp of Florida is a holding company. The company provides integrated financial services, including commercial and consumer banking, wealth management, and mortgage and insurance services, to customers across Florida through branch, mobile, and online banking solutions. It maintains day-to-day operations, particularly in the areas of operations, treasury management systems, information technology, and security. The company has one reportable segment that provides these integrated financial services, with segment revenues driven mainly by interest and fees on loans, interest on cash and cash equivalents, and investment securities, and fees on depository products and services.